QIAGEN Reports Strong Third Quarter 2009 Results
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ * 16% Revenue Growth on Constant Exchange Rates * 15% Organic Revenue Growth * 31% Operating Margin, adjusted * $0.26 Adjusted EPSVenlo, The Netherlands, November 9, 2009 - QIAGEN N.V. (Nasdaq: QGEN;Frankfurt, Prime Standard: QIA) today announced the results ofoperations for the third quarter and the nine-month period endedSeptember 30, 2009.The reported net sales and the adjusted earnings per share for thethird quarter 2009 exceeded the guidance provided by the Company onAugust 11, 2009.Third Quarter 2009 ResultsQIAGEN's Third Quarter 2009 (in US$ millions, except per shareinformation) Q3 2009 Q3 2008 GrowthNet sales 259.7 230.8 13 %Net sales at constant exchange rates 268.7 230.8 16 %Operating income, adjusted 81.8 66.8 22 %Net income, adjusted 53.5 42.4 26 %EPS, adjusted (US$) 0.26 0.21 24 %For information on the adjusted figures, please refer to thereconciliation tableaccompanying this release.The Company reported that consolidated net sales for its thirdquarter 2009 increased 13% to $259.7 million from $230.8 million inthe same quarter of 2008. Excluding the unfavorable impact fromforeign currency exchange rates, net sales for the third quarter 2009would have increased 16%. The reported operating income for thequarter increased 40% to $53.4 million from $38.2 million in the samequarter of 2008, and net income for the quarter increased 81% to$37.7 million from $20.8 million in the same quarter of 2008. Dilutedearnings per share for the third quarter increased 80% to $0.18 in2009 from $0.10 in 2008.On an adjusted basis, third quarter operating income increased 22% to$81.8 million in 2009 from $66.8 million in 2008, and third quarter2009 adjusted net income increased 26% to $53.5 million from $42.4million in 2008. Adjusted diluted earnings per share increased 24% to$0.26 in the third quarter 2009 from $0.21 in 2008.Nine-Month Period 2009 ResultsFor the nine-month period ended September 30, 2009, net salesincreased 10% to $720.7 million compared to $655.8 million in thesame period of 2008. Operating income as reported for the nine monthsended September 30, 2009 increased 30% to $137.3 million from $105.2million for the same period in 2008. Net income increased 45% to$93.3 million from $64.4 million in 2008, and diluted earnings pershare increased 45% to $0.45 in 2009 from $0.31 in 2008.On an adjusted basis, operating income for the nine-month periodended September 30, 2009 increased 14% to $212.7 million in 2009 from$186.1 million in 2008, and adjusted net income increased 19% to$142.0 million from $119.6 million. Adjusted diluted earnings pershare in the nine months ended September 30, 2009 increased 19% to$0.69 per share from $0.58 per share in the same period of 2008.QIAGEN's third quarter and nine-month period 2009 results include theresults of operations from the Company's recent acquisitions, themost significant of which was DxS Ltd., acquired in September 2009,and Corbett Life Science, acquired in July 2008. Reconciliations ofreported results determined in accordance with generally acceptedaccounting principles (GAAP) to adjusted results are included in thetables accompanying this release."We are very pleased with our financial performance in the thirdquarter of 2009," said Peer Schatz, QIAGEN's Chief Executive Officer."We saw strong growth in revenues, operating margins and adjusted netincome - all of which exceeded our guidance. In addition, our organicrevenue growth came in very strong at 15%.""Revenue growth was highest in sales to customers in moleculardiagnostics (approximately 50% of total revenues) followed by salesto customers in pharma (approximately 21% of total revenues), inapplied testing (approximately 6% of total revenues) and in academia(approximately 23% of total revenues). Growth of our sales tocustomers in molecular diagnostics was fueled by strong sales of our"prevention" products (primarily HPV screening),"personalized healthcare" assays (including our KRAS testing solutions) and profilingsolutions (including our influenza and other infectious diseaseassays). Sales to customers in the pharmaceutical and biotechindustry conducting clinical development continued to experiencesolid growth and sales to customers in pharma discovery areimproving. The academic research markets continued to perform solidlyand we are looking forward to the effect of the stimulus programswhich are expected for 2010.""The markets we serve demonstrated robust demand and solid economictrends. We are very pleased with the strategic momentum we were ableto build since the announcement of our second quarter results inAugust. Since August we have announced the following acquisitions: * The pending acquisition of SABiosciences will add to QIAGEN a portfolio of PCR-based, pathway-focused panels that represent highly efficient solutions for pathway- and disease-biomarker discovery and development in pharmaceutical and biomedical research. The efforts associated with the validation of such biomarkers can at the same time serve as engines for novel content for molecular diagnostics. * The acquisition of DxS Ltd. combines two leadership positions to create a very powerful leader in a transformational area of healthcare: personalized healthcare.Both transactions are key elements of our strategy to lead inmolecular diagnostics-based prevention, profiling and personalizedhealthcare. These three pillars of our molecular diagnostics strategyare expected to significantly shape and contribute to futureimprovements in healthcare and have the potential to providesignificant benefits to patients as well as exceptional value forpayers, providers, and the pharmaceutical industry.""QIAGEN experienced a successful third quarter. Reported revenues andadjusted earnings per share exceeded our expectations," said RolandSackers, QIAGEN's Chief Financial Officer. "Assuming constantexchange rates for both quarters, and adjusted for the divesture ofcertain assets related to our activities in HLA diagnostics(transplantation diagnostics), revenue growth was 18% and was fueledby a strong organic growth of 15% and a positive contribution of 3%from acquisitions.Our consumable products portfolio contributed 12% growth (16% atconstant exchange rates) and our sales of instrumentation productsrecorded a growth rate of 18% (23% at constant exchange rates). Netsales in the Americas for the third quarter 2009 representedapproximately 51% of our overall business and recorded a growth rateof 12% (15% at constant exchange rates) and European sales, whichrepresent approximately 35% of our revenues, showed a growth rate of16% (24% at constant exchange rates). Net sales in Asia remainedstrong, showing a growth rate of 41% (37% at constant exchangerates)."Increase of Fiscal Year 2009 Guidance RangeBased on the successful first nine months and a positive outlook forthe rest of the year, QIAGEN is increasing its expectations foradjusted diluted earnings per share for the fiscal year 2009 from theprevious range of $0.86 to $0.90 (based on a weighted average numberof fully diluted shares outstanding of approximately 214 millionfollowing the equity offering in September 2009) to now between $0.88and $0.90 based on foreign currency exchange rates as of January 31,2009.QIAGEN - Sample and Assay Technologies Highlights * In September, QIAGEN acquired DxS Ltd., a developer and manufacturer of companion diagnostic products (CDx) for Personalized Healthcare (PHC). With this acquisition, QIAGEN has added to its own activities in CDx and taken a strong leadership position in the new era of PHC. The Company believes it offers all the required elements to help drive and shape this rapidly emerging trend in healthcare. The acquisition of DxS brings to QIAGEN a portfolio of molecular diagnostic assays and intellectual property, as well as a deep pipeline of active or planned companion diagnostic partnerships in oncology with many of the leading pharmaceutical companies, including Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca and others. These assets complement QIAGEN's strong existing portfolio of personalized healthcare diagnostic solutions and are very synergistic with QIAGEN's sample and assay technologies. * In November, QIAGEN announced that it is in the process of acquiring SABiosciences. This transaction will add to QIAGEN's product offering a leading portfolio of PCR-based, disease and pathway-based panels that play key roles in biomedical research and the development of future drugs and diagnostics. The offerings from SABiosciences can significantly increase QIAGEN's footprint in the rapidly emerging segment of molecular analysis-based clinical development in pharmaceutical and biomedical research. In addition, the use of these panels and the resulting validation of select biomarkers from these panels by institutions conducting biomedical and pharmaceutical research has the potential to serve as a unique engine to support the expansion of the test menu for QIAGEN's diagnostics platforms - in particular in the area of personalized health care but also in prevention and profiling. As such, this transaction is highly synergistic with QIAGEN's activities in the fast growing segments of solutions for pharmaceutical development and molecular diagnostics. * In September, QIAGEN and Merck & Co., Inc. announced the creation of a joint program to increase access to HPV vaccination and HPV DNA testing in some of the poorest areas of the world. This initiative is the first collaboration of a vaccine manufacturer and a molecular diagnostics company to address the burden of cervical cancer with a comprehensive approach. Representing a combined value of approximately $600 million based on current U.S. prices, the commitments of QIAGEN and Merck were highlighted among a select group of corporate initiatives announced at the annual meeting of the Clinton Global Initiative in September. QIAGEN intends to add to its existing one million test donation program by providing the digene HC2 HPV DNA Test (as known as the digene HPV Test) and a new HPV DNA test that is currently in development for use specifically in the developing world to screen an additional 500,000 women. In addition, Merck intends to provide up to five million free doses of its cervical cancer vaccine, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and18) Vaccine Recombinant]. * In September, QIAGEN opened its new Asia headquarters in Zhangjiang High-Tech Park, Pudong, Shanghai, China. QIAGEN established Shanghai as the location for its Asia headquarters in 2006. Resources and employees that were previously spread across different locations have been brought together at the new site in Zhangjiang High-Tech Park - which has emerged as the biotechnology hub of China. Zhangjiang High-Tech Park is home to 15 multinational pharmaceutical R&D centers, 32 Contract Research Organization (CRO) companies, 29 major pharma manufacturing plants and over 200 biotech-pharma companies. QIAGEN's new facility provides better access to the Company's new technologies and applications and reduces delivery time to thousands of scientists working in the Park. * In the first nine months of 2009, QIAGEN launched more than 48 new products in the area of Sample & Assay Technologies including a range of applications used to analyze genetic differences between individuals or cells, the Type-it® HRM PCR Kit and Rotor-Gene® ScreenClust HRM Software. HRM (high resolution melting) technology enabling fast, accurate genotyping results. In addition QIAGEN launched a new PCR-based Influenza A/H1N1 test that enables both the highly sensitive and specific detection of the novel Influenza A/H1N1, the virus that causes "swine flu", as well as of all other known Influenza A and B virus strains and several QIAsafe DNA Blood Products, the first dry blood storage solutions available on a matrix, based on Biomatrica's innovative SampleMatrix® technology. * In September, QIAGEN placed 31.6 million shares (including the full exercise of an over-allotment option) at a price of $20.25 per share. QIAGEN used and expects to use the net proceeds of approximately $624 million to fund the acquisition of DxS Ltd. as well as potential future acquisitions, to strengthen its balance sheet and for general corporate purposes. * In October, QIAGEN started the relocation of its activities in Brisbane and Sydney to other locations of the Company, primarily to QIAGEN Instruments AG in Switzerland. The restructurings follow the acquisition of Corbett in 2008 and consolidate QIAGEN's instrument manufacturing activities. The closure and relocation is intended to be completed in the second quarter of 2010 and is expected to result in an increase in QIAGEN's future profitability. QIAGEN expects to incur total restructuring charges of approximately $4 to $5 million before taxes for the remainder of fiscal 2009 and fiscal 2010.Conference Call and Webcast DetailsDetailed information on QIAGEN's business and financial performancewill be presented during its conference call on November 10, 2009 at9:30am ET. The corresponding presentation slides will be availablefor download on the Company's website atwww.qiagen.com/goto/ConferenceCall. A webcast of the conference callwill also be available at www.qiagen.com/goto/ConferenceCall.Use of Adjusted ResultsQIAGEN has regularly reported adjusted results to give additionalinsight into its financial performance as well as considered resultson a constant currencies basis. Adjusted results should be consideredin addition to the reported results prepared in accordance withgenerally accepted accounting principles, but should not beconsidered as a substitute. The Company believes certain items shouldbe excluded from adjusted results when they are outside of itsongoing core operations, vary significantly from period to period, oraffect the comparability of results with the Company's competitorsand its own prior periods. Reconciliations of reported results toadjusted results are included in the tables accompanying thisrelease.About QIAGENQIAGEN N.V., a Netherlands holding company, is the leading globalprovider of sample and assay technologies. Sample technologies areused to isolate and process DNA, RNA and proteins from biologicalsamples such as blood or tissue. Assay technologies are used to makethese isolated biomolecules visible. QIAGEN has developed and marketsmore than 500 sample and assay products as well as automatedsolutions for such consumables. The Company provides its products tomolecular diagnostics laboratories, academic researchers,pharmaceutical and biotechnology companies, and applied testingcustomers for purposes such as forensics, animal or food testing andpharmaceutical process control. QIAGEN's assay technologies includeone of the broadest panels of molecular diagnostic tests availableworldwide. This panel includes the first FDA-approved test for humanpapillomavirus (HPV), the primary cause of cervical cancer. QIAGENemploys more than 3,300 people in over 30 locations worldwide.Further information about QIAGEN can be found athttp://www.qiagen.com/.Certain of the statements contained in this news release may beconsidered forward-looking statements within the meaning of Section27A of the U.S. Securities Act of 1933, as amended, and Section 21Eof the U.S. Securities Exchange Act of 1934, as amended. To theextent that any of the statements contained herein relating toQIAGEN's products, markets, strategy or operating results areforward-looking, such statements are based on current expectationsthat involve a number of uncertainties and risks. Such uncertaintiesand risks include, but are not limited to, risks associated withmanagement of growth and international operations (including theeffects of currency fluctuations and risks of dependency onlogistics), variability of operating results, the commercialdevelopment of the applied testing markets, clinical research marketsand proteomics markets, women's health/HPV testing markets, nucleicacid-based molecular diagnostics market, and genetic vaccination andgene therapy markets, changing relationships with customers,suppliers and strategic partners, competition, rapid or unexpectedchanges in technologies, fluctuations in demand for QIAGEN's products(including fluctuations due to general economic conditions, the leveland timing of customers' funding, budgets, and other factors), ourability to obtain regulatory approval of our infectious diseasepanels, difficulties in successfully adapting QIAGEN's products tointegrated solutions and producing such products, the ability ofQIAGEN to identify and develop new products and to differentiate itsproducts from competitors' products, market acceptance of QIAGEN'snew products and the integration of acquired technologies andbusinesses. In addition certain statements contained in this newsrelease are based on company assumptions, including, but not limited,to revenue allocations based on business segments. For furtherinformation, refer to the discussions in reports that QIAGEN hasfiled with, or furnished to, the U.S. Securities and ExchangeCommission (SEC). # # # QIAGEN N.V. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) Three months(in thousands, except per share data) ended September 30, 2009 2008Net sales $ 259,659 $ 230,800 Cost of sales 86,647 77,861Gross profit 173,012 152,939Operating expenses: Research and development 26,747 24,073 Sales and marketing 60,719 55,972 General and administrative, integration andother 27,805 29,868 Purchased in-process research anddevelopment - 830 Acquisition related intangible amortization 4,387 4,018Total operating expenses 119,658 114,761Income from operations 53,354 38,178Other income (expense): Interest income 678 2,095 Interest expense (7,405) (9,194) Other income, net 2,692 (3,233)Total other expense (4,035) (10,332)Income before provision for income taxes andnoncontrolling interest 49,319 27,846Provision for income taxes 11,629 6,679Net income 37,690 21,167Less: Noncontrolling interest - 376Net income attributable to QIAGEN N.V. $ 37,690 $ 20,791 Weighted average number of diluted commonshares 208,316 204,600 Diluted net income attributable to QIAGEN $ $N.V. per common share 0.18 0.10 Diluted net income attributable to QIAGENN.V. per common share, adjusted $ 0.26 $ 0.21 QIAGEN N.V. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) Nine months(in thousands, except per share data) ended September 30, 2009 2008Net sales $ 720,748 $ 655,794 Cost of sales 241,787 213,555Gross profit 478,961 442,239Operating expenses: Research and development 77,340 69,281 Sales and marketing 175,857 167,746 General and administrative, integration andother 76,210 88,672 Purchased in-process research anddevelopment - 830 Acquisition related intangible amortization 12,289 10,484Total operating expenses 341,696 337,013Income from operations 137,265 105,226Other income (expense): Interest income 2,541 7,391 Interest expense (22,136) (28,832) Other income, net 5,249 (672)Total other expense (14,346) (22,113)Income before provision for income taxes andnoncontrolling interest 122,919 83,113Provision for income taxes 29,616 18,272Net income 93,303 64,841Less: Noncontrolling interest - 491Net income attributable to QIAGEN N.V. $ 93,303 $ 64,350 Weighted average number of diluted commonshares 205,096 204,999 Diluted net income attributable to QIAGENN.V. per common share $ 0.45 $ 0.31 Diluted net income attributable to QIAGENN.V. per common share, adjusted $ 0.69 $ 0.58 QIAGEN N.V. CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, except par value) September 30, 2009 December 31,Assets (unaudited) 2008Current Assets:Cash and cash equivalents $ 861,273 $ 333,313Accounts receivable, net 181,692 158,440Income taxes receivable 27,843 14,441Inventories, net 133,618 108,563Prepaid expenses and other 135,192 61,424Deferred income taxes 32,543 27,374Total current assets 1,372,161 703,555Long-Term Assets:Property, plant and equipment, net 310,215 289,672Goodwill 1,273,754 1,152,105Intangible assets, net 693,777 640,309Deferred income taxes 78,016 73,766Other assets 26,728 25,916Total long-term assets 2,382,490 2,181,768Total assets $ 3,754,651 $ 2,885,323Liabilities and Shareholders' EquityCurrent Liabilities:Accounts payable $ 42,078 $ 48,836Accrued and other liabilities 236,980 163,513Income taxes payable 33,414 14,288Current portion of long-term debt 50,000 25,000Current portion of capital leaseobligations 3,342 2,984Deferred income taxes 10,256 7,754Total current liabilities 376,070 262,375Long-Term Liabilities:Long-term debt, net of current portion 870,000 920,000Capital lease obligations, net of currentportion 28,797 29,718Deferred income taxes 237,530 212,589Other 13,945 6,797Total long-term liabilities 1,150,272 1,169,104Shareholders' Equity:Common shares, EUR .01 par value:Authorized--410,000 sharesIssued and outstanding--231,130 sharesin 2009 and 197,839 shares in 2008 2,697 2,212Additional paid-in-capital 1,606,218 958,665Retained earnings 571,115 477,812Accumulated other comprehensive income 48,279 15,155Total QIAGEN N.V. shareholders' equity 2,228,309 1,453,844Total liabilities and shareholders' equity $ 3,754,651 $ 2,885,323 Three months ended September 30, 2009 (in thousands, except EPS data) Net Gross Operating Pre-tax Net Diluted Sales Profit Income Income Income Tax Income EPS*Reportedresults $ 259,659 $ 173,012 $ 53,354 $ 49,319 $ (11,629) $ 37,690 $ 0.18Adjustments:Businessintegration,acquisitionrelatedandrestructuringcosts - 177 2,790 2,790 (918) 1,872 0.01Purchasedintangiblesamortization - 13,111 17,499 17,499 (6,082) 11,417 0.06Share-basedcompensation - 245 2,348 2,348 (678) 1,670 0.01Acquisitionof DxS Ltd. - 2,515 5,784 5,784 (1,661) 4,123 0.02Transfer ofOlerup SSPbusiness andotheracquisitionrelatedincome - - - (2,429) (835) (3,264) (0.02)Totaladjustments - 16,048 28,421 25,992 (10,174) 15,818 0.08Adjustedresults $ 259,659 $ 189,060 $ 81,775 $ 75,311 $ (21,803) $ 53,508 $ 0.26Using 208,316dilutedshares Three months ended September 30, 2008 (in thousands, except EPS data) Gross Operating Pre-tax Net Diluted Net Sales Profit Income Income Income Tax Income EPS*Reportedresults $ 230,800 $ 152,939 $ 38,178 $ 27,846 $ (6,679) $ 20,791 $ 0.10Adjustments:Businessintegration,acquisitionrelatedandrestructuringcosts - 396 9,122 9,122 (3,138) 5,984 0.03Purchasedin-processR&D - - 830 830 - 830 -Purchasedintangiblesamortization - 12,776 16,794 16,794 (5,876) 10,918 0.06Share-basedcompensation - 223 1,896 1,896 (580) 1,316 0.01Acquisitionrelatedimpairment - - - 4,000 (1,480) 2,520 0.01Totaladjustments - 13,395 28,642 32,642 (11,074) 21,568 0.11Adjustedresults $ 230,800 $ 166,334 $ 66,820 $ 60,488 $ (17,753) $ 42,359 $ 0.21* Using 204,600 diluted shares QIAGEN N.V. RECONCILIATION OF REPORTED TO ADJUSTED FIGURES (unaudited) Nine months ended September 30, 2009 (in thousands, except EPS data) Gross Operating Pre-tax Net Diluted Net Sales Profit Income Income Income Tax Income EPS*Reportedresults $ 720,748 $ 478,961 $ 137,265 $ 122,919 $ (29,616) $ 93,303 $ 0.45Adjustments:Businessintegration,acquisitionrelatedandrestructuringcosts - 688 10,705 10,705 (3,396) 7,309 0.04Purchasedintangiblesamortization - 39,290 51,579 51,579 (17,973) 33,606 0.17Share-basedcompensation - 699 7,352 7,352 (2,229) 5,123 0.02Acquisitionof DxS Ltd. - 2,515 5,784 5,784 (1,661) 4,123 0.02Transfer ofOlerup SSPbusiness andother -acquisitionrelatedincome - - (2,429) (835) (3,264) (0.02)Acquisitionrelatedwrite-off ofprepaidexpenses andother assetimpairment - - - 2,703 (870) 1,833 0.01Totaladjustments - 43,192 75,420 75,694 (26,964) 48,730 0.24Adjustedresults $ 720,748 $ 522,153 $ 212,685 $ 198,613 $ (56,580) $ 142,033 $ 0.69* Using 205,096 diluted shares Nine months ended September 30, 2008 (in thousands, except EPS data) Net Gross Operating Pre-tax Net Diluted Sales Profit Income Income Income Tax Income EPS*Reportedresults $ 655,794 $ 442,239 $ 105,226 $ 83,113 $ (18,272) $ 64,350 $ 0.31Adjustments:Businessintegration,acquisitionrelatedandrestructuringcosts - 396 27,723 27,723 (9,760) 17,963 0.09Purchasedin-processR&D - - 830 830 - 830 -Purchasedintangiblesamortization - 35,551 46,035 46,035 (16,306) 29,729 0.15Share-basedcompensation - 763 6,251 6,251 (2,001) 4,250 0.02Acquisitionrelatedimpairment - - - 4,000 (1,480) 2,520 0.01Totaladjustments - 36,710 80,839 84,839 (29,547) 55,292 0.27Adjustedresults $ 655,794 $ 478,949 $ 186,065 $ 167,952 $ (47,819) $ 119,642 $ 0.58* Using204,999dilutedsharesContacts:Roland Sackers Dr. Solveigh MählerChief Financial Officer Director Investor RelationsQIAGEN N.V. QIAGEN N.V.e-mail: +49 2103 29 11710roland.sackers(at)qiagen.com e-mail: solveigh.maehler(at)qiagen.com Albert F. Fleury Associate Director Investor Relations North America QIAGEN N.V. +1 301 944 7028 e-mail: albert.fleury(at)qiagen.com --- End of Message ---Qiagen N.V.Spoorstraat 50 KJ Venlo NetherlandsWKN: 901626; ISIN: NL0000240000; Index: HDAX, MIDCAP, Prime All Share, TECH All Share, TecDAX;Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;
Datum: 09.11.2009 - 22:00 Uhr
Sprache: Deutsch
News-ID 8134
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 246 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"QIAGEN Reports Strong Third Quarter 2009 Results"
steht unter der journalistisch-redaktionellen Verantwortung von
Qiagen N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
